Tetra Bio-Pharma Announces Expected Effective Date of Listing on TSX of its Common Shares and Warrants

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

OTTAWA, ON, July 30, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the previously announced graduation of the Corporation's common shares (the "Common Shares") and listed warrants (the "Warrants") is expected to occur on August 4, 2020.

The Corporation previously announced on July 15, 2020 that it had received conditional approval from the Toronto Stock Exchange ("TSX") to graduate from the TSX-Venture Exchange ("TSX-V"), where the Common Shares and certain of its Warrants are currently listed, subject to satisfying certain standard listing requirements.

The graduation is expected to occur on August 4, 2020, and the Common Shares and Warrants are expected to be listed and commence trading on the TSX at the opening of markets on same date under the symbols "TBP", "TBP.WT", "TBP.WT.A" and "TBP.WT.B", respectively. In connection with such graduation, the Corporation's Common Shares and listed Warrants will be voluntarily delisted from the TSX-V. The Common Shares will continue to trade on the OCTQB market under the symbol "TBPMF".

The Common Shares and Warrants have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

This press release does not constitute an offer to sell or a solicitation of any offer to buy the securities in the United States, in any province or territory of Canada or in any other jurisdiction. There shall be no sale of the securities in any jurisdiction in which an offer to sell, a solicitation of an offer to buy or sale would be unlawful.

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Corporation has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com  

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, the listing of the Common Shares and the listed Warrants on the TSX and the delisting of the Common Shares and listed Warrants from the TSX-V) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Corporation to obtain sufficient financing to execute the Corporation's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation's public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

SOURCE Tetra Bio-Pharma Inc.

please contact Tetra Bio-Pharma Inc.: Investor Contact: Alpha Bronze, LLC, Mr. Pascal Nigen, Phone: + 1 [phone], [email protected]; Media Contact: energi PR, Ms. Carol Levine, APR, FCPRS, Phone: + 1 [phone] ext. 226, Mobile: + 1 [phone], [email protected]

Related Links

https://tetrabiopharma.com/